Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms

被引：1

作者：

Luo, Ming ^{[1
]}

Tian, Tingting ^{[1
]}

Zhang, Yaofang ^{[1
]}

Zhang, Xialin ^{[1
]}

Xie, Juan ^{[1
]}

Xu, Jing ^{[1
]}

Ren, Weixiao ^{[1
]}

Tian, Chuchu ^{[1
]}

Wang, Jiaxuan ^{[1
]}

Tan, Yanhong ^{[1
]}

Wang, Hongwei ^{[1
]}

Chen, Xiuhua ^{[1
]}

机构：

[1] Shanxi Med Univ, Hosp 2, Inst Hematol, 382 Wuyi Rd, Taiyuan 030001, Peoples R China

来源：

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2021年 / 43卷 / 03期

基金：

中国国家自然科学基金;

关键词：

atypical mutation; JAK2; myeloproliferative neoplasms; PSEUDOKINASE DOMAIN;

D O I：

10.1111/ijlh.13398

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E110 / E113

页数：4

共 50 条

[1] JAK2 and MPL mutations in myeloproliferative neoplasms
Koppikar, Priya
Levine, Ross L.
ACTA HAEMATOLOGICA, 2008, 119 (04) : 218 - 225
[2] JAK2 mutations and clinical practice in myeloproliferative neoplasms
Tefferi, Ayalew
CANCER JOURNAL, 2007, 13 (06): : 366 - 371
[3] JAK2 mutations in myeloproliferative neoplasms: a 2008 update
Guerin, Estelle
Praloran, Vincent
Lippert, Eric
HEMATOLOGIE, 2008, 14 (05): : 368 - 377
[4] Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Passamonti, Francesco
Maffioli, Margherita
Caramazza, Domenica
Cazzola, Mario
ONCOTARGET, 2011, 2 (06) : 485 - 490
[5] JAK2 Exons 12, 13, 14, and 15 Mutation Analysis
Cai, L.
Howitt, J.
Wang, D.
Eisenberg, M.
Boles, D.
Chenn, A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1144 - 1144
[6] Myeloproliferative Neoplasms: The Era of JAK2 Mutations and More...
Saxena, Renu
Gupta, Sanjeev Kumar
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (04) : 4 - 5
[7] Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J.
Massie, C. E.
Baxter, E. J.
Nice, F. L.
Gundem, G.
Wedge, D. C.
Avezov, E.
Li, J.
Kollmann, K.
Kent, D. G.
Aziz, A.
Godfrey, A. L.
Hinton, J.
Martincorena, I.
Van Loo, P.
Jones, A. V.
Guglielmelli, P.
Tarpey, P.
Harding, H. P.
Fitzpatrick, J. D.
Goudie, C. T.
Ortmann, C. A.
Loughran, S. J.
Raine, K.
Jones, D. R.
Butler, A. P.
Teague, J. W.
O'Meara, S.
McLaren, S.
Bianchi, M.
Silber, Y.
Dimitropoulou, D.
Bloxham, D.
Mudie, L.
Maddison, M.
Robinson, B.
Keohane, C.
Maclean, C.
Hill, K.
Orchard, K.
Tauro, S.
Du, M-Q
Greaves, M.
Bowen, D.
Huntly, B. J. P.
Harrison, C. N.
Cross, N. C. P.
Ron, D.
Vannucchi, A. M.
Papaemmanuil, E.
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (25): : 2391 - 2405
[8] Frequency of JAK2 Mutations in Patients with Suspected Myeloproliferative Neoplasms
Judd, A.
Chabot-Richards, D.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1138 - 1138
[9] JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
O Kilpivaara
R L Levine
Leukemia, 2008, 22 : 1813 - 1817
[10] Targeting JAK2 pathway mutations for treatment of myeloproliferative neoplasms
Purandare, Ashok V.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244

← 1 2 3 4 5 →